Skip to main content

ANBL1531 A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma

NCT03126916

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma

Associated Conditions

Brain Cancer

Principal Investigator

Sponsor

Children's Oncology Group

The overall goals of this study are to: Compare the effects, good and/or bad, of the experimental drug 131I-MIBG added to current COG recommended therapy to the effects of current COG recommended therapy without the experimental drug 131I-MIBG. Compare the effects, good and/or bad, of the experimental drug crizotinib added to current COG recommended therapy to the effects of current COG recommended therapy without the experimental drug crizotinib.

This study is currently enrolling.